Armaan Nallicheri, Katherine M Mahoney, Hanna A Gutow, Natalie Bellini, Diana Isaacs
{"title":"Review of Automated Insulin Delivery Systems for Type 1 Diabetes and Associated Time in Range Outcomes.","authors":"Armaan Nallicheri, Katherine M Mahoney, Hanna A Gutow, Natalie Bellini, Diana Isaacs","doi":"10.17925/EE.2022.18.1.27","DOIUrl":null,"url":null,"abstract":"<p><p>Automated insulin delivery (AID) systems play an important role in the management of type 1 diabetes mellitus (T1DM). These systems include three components: a continuous glucose monitor (CGM), an insulin pump and an algorithm that adjusts the pump based on the CGM sensor glucose readings. They are not fully automated and still require the user to administer bolus insulin doses for food. Some AID systems have automatic correction boluses, while others only have automatic basal or background insulin adjustments. As CGM has become more accurate and the technology has evolved, AID systems have demonstrated improved glycaemic outcomes. The clinical evaluation of AID systems in randomized controlled trials and real-world studies have shown their utility in helping glycaemic management. In this review, we compare AID systems that are commercially available in the US and summarize the literature, with a special focus on time in range in T1DM. The review also discusses new AID systems on the horizon and explores considerations for personalized care.</p>","PeriodicalId":75231,"journal":{"name":"TouchREVIEWS in endocrinology","volume":"18 1","pages":"27-34"},"PeriodicalIF":0.0000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354504/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"TouchREVIEWS in endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17925/EE.2022.18.1.27","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/5/20 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Automated insulin delivery (AID) systems play an important role in the management of type 1 diabetes mellitus (T1DM). These systems include three components: a continuous glucose monitor (CGM), an insulin pump and an algorithm that adjusts the pump based on the CGM sensor glucose readings. They are not fully automated and still require the user to administer bolus insulin doses for food. Some AID systems have automatic correction boluses, while others only have automatic basal or background insulin adjustments. As CGM has become more accurate and the technology has evolved, AID systems have demonstrated improved glycaemic outcomes. The clinical evaluation of AID systems in randomized controlled trials and real-world studies have shown their utility in helping glycaemic management. In this review, we compare AID systems that are commercially available in the US and summarize the literature, with a special focus on time in range in T1DM. The review also discusses new AID systems on the horizon and explores considerations for personalized care.
胰岛素自动给药系统(AID)在 1 型糖尿病(T1DM)的治疗中发挥着重要作用。这些系统包括三个组成部分:连续血糖监测仪(CGM)、胰岛素泵和根据 CGM 传感器血糖读数调整泵的算法。这些系统并非完全自动化,仍需要用户为食物注射胰岛素。有些 AID 系统具有自动校正胰岛素剂量的功能,而有些则只有自动调整基础或背景胰岛素的功能。随着 CGM 的精确度提高和技术的发展,AID 系统的血糖治疗效果也得到了改善。在随机对照试验和实际研究中对 AID 系统进行的临床评估表明,它们在帮助进行血糖管理方面非常有用。在这篇综述中,我们比较了美国市售的 AID 系统,并总结了相关文献,特别关注了 T1DM 患者的血糖控制时间。综述还讨论了即将推出的新型 AID 系统,并探讨了个性化护理的注意事项。